Abstract
A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
Keywords: Multidrug, extensively-drug, resistant, tuberculosis, compounds, novel, patents
Recent Patents on Anti-Infective Drug Discovery
Title:Novel Compounds and Drugs and Recent Patents in Treating Multidrug- Resistant and Extensively Drug-Resistant Tuberculosis
Volume: 7 Issue: 2
Author(s): Attapon Cheepsattayakorn and Ruangrong Cheepsattayakorn
Affiliation:
Keywords: Multidrug, extensively-drug, resistant, tuberculosis, compounds, novel, patents
Abstract: A number of recent studies revealed that successful treatment of the patients with MDR/XDR- TB was not achieved due to high resistant rates to many second-line drugs such as kanamycin and prothionamide including poor adherence of the lengthy treatment. Many new drugs and compounds such as benzothiazinones, meropenem, PA-824, isoflavonoids, rhein, PNU-100480, TMC207, SQ109, OPC-67683, AZD5847, and linezolid are currently in development pipeline. According to very few patents in new compounds and drugs against MDR/XDRMycobacterium tuberculosis bacilli have been currently introduced, so inventors must be encouraged to contribute to this area worldwide.
Export Options
About this article
Cite this article as:
Cheepsattayakorn Attapon and Cheepsattayakorn Ruangrong, Novel Compounds and Drugs and Recent Patents in Treating Multidrug- Resistant and Extensively Drug-Resistant Tuberculosis, Recent Patents on Anti-Infective Drug Discovery 2012; 7 (2) . https://dx.doi.org/10.2174/157489112801619683
DOI https://dx.doi.org/10.2174/157489112801619683 |
Print ISSN 1574-891X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4071 |
Related Articles
-
Evaluation of Arthritis in Hanseniase
Current Rheumatology Reviews Diagnosis and Therapeutic Approaches to Transthyretin Amyloidosis
Current Medicinal Chemistry Danger-Detector NKG2D: Immunosurveillance of Induced Self and Modulation by Cytokines and Soluble Ligands
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Progress in Structure-Based Design of EGFR Inhibitors
Current Drug Targets Recent Developments in the Electrochemistry of Some Nitro Compounds of Biological Significance
Current Organic Chemistry The CD4C/HIVNef Transgenic Model of AIDS
Current HIV Research Graphical Abstracts
Medicinal Chemistry Formulation Strategies and Particle Engineering Technologies for Pulmonary Delivery of Biopharmaceuticals
Current Pharmaceutical Design Drug-Induced Hypokalaemia
Current Drug Safety Targeted Drug Delivery Across the Blood Brain Barrier in Alzheimer’s Disease
Current Pharmaceutical Design Molecular Topology and Other Promiscuity Determinants as Predictors of Therapeutic Class - A Theoretical Framework to Guide Drug Repositioning?
Current Topics in Medicinal Chemistry Editorial [Hot Topic: Carbonic Anhydrases: Again, and Again, and Again (Executive Editor: Claudiu T. Supuran)]
Current Pharmaceutical Design Pharmacogenetic Polymorphisms in a Portuguese Gypsy Population
Current Pharmacogenomics and Personalized Medicine Design and In Vitro Evaluation of Five Inhibitors of Mycobacterium Tuberculosis
Letters in Drug Design & Discovery Epipolythiodioxopiperazines from Fungi: Chemistry and Bioactivities
Mini-Reviews in Medicinal Chemistry Optimal Antibiotic Therapy in the Management of the Lung of the Critically Ill
Current Respiratory Medicine Reviews Preface
Combinatorial Chemistry & High Throughput Screening HIF-1α Deficiency Perturbs T and B Cell Functions
Current Pharmaceutical Design Dry Powder Formulation of Plasmid DNA and siRNA for Inhalation
Current Pharmaceutical Design Vesicular Carriers for Skin Drug Delivery: The Pheroid™ Technology
Current Pharmaceutical Design